

Title: Breast Cancer Treatments

Reference Number: RDF1321-23

Date of Response: 15/03/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Dear Royal Devon University Healthcare NHS Foundation Trust,

I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following two questions.

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

Answer: Please see table below representing the latest available data September 2022 to November 2022.

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤ 5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients/staff and should not be published.

	<i>Trust Response</i>
<i>Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)</i>	Nil
<i>Abemaciclib + Fulvestrant</i>	6
<i>Alpelisib + Fulvestrant</i>	Nil
<i>Anthracycline (e.g. doxorubicin or epirubicin) as a single agent</i>	Nil
<i>Atezolizumab + Nab-paclitaxel/Paclitaxel</i>	≤ 5
<i>Capecitabine as a single agent</i>	20
<i>Eribulin as a single agent or in combination</i>	10
<i>Everolimus + Exemestane</i>	≤ 5
<i>Fulvestrant as a single agent</i>	Nil
<i>Lapatinib</i>	Nil
<i>Neratinib</i>	Nil
<i>Parp Inhibitors (Olaparib/Talazoparib)</i>	Nil
<i>Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)</i>	60
<i>Palbociclib + Fulvestrant</i>	17
<i>Pembrolizumab</i>	Nil
<i>Platinum (e.g. carboplatin or cisplatin) as a single agent</i>	≤ 5
<i>Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)</i>	27

<i>Ribociclib + Fulvestrant</i>	8
<i>Sacituzumab Govitecan</i>	≤5
<i>Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent</i>	51
<i>Taxane and/or Anthracycline in combination</i>	Nil
<i>Trastuzumab as a single agent or in combination</i>	88
<i>Trastuzumab emtansine</i>	10
<i>Trastuzumab deruxtecan</i>	≤5
<i>Any other active systemic anti-cancer therapy</i>	151

Q2. Of the patients treated for breast cancer with Abemaciclib + Aromatase Inhibitor in the past the 3 months, please provide the number of patients with:

Answer: Please see table below representing the latest available data September 2022 to November 2022.

	<i>Trust Response</i>
<i>early/locally advanced breast cancer (Stages 1 to 3B)</i>	Nil
<i>advanced/metastatic breast cancer (Stages 3C and 4)</i>	Nil